Stay at the forefront of biopharmaceutical innovation. Subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Related to this article

September 30th, 2026

The BioPharm Brief: Pills, Skin, and Biosimilars

Real-world data show weight loss after switching to the Wegovy pill, Lilly reports positive hand and foot atopic dermatitis data, and Teva wins FDA approval for a Xgeva biosimilar.

Injection pens lying next to white oral tablets on a blue surface. | Image Credit: © Andreas Prott - stock.adobe.com

September 30th, 2026

Wegovy Pill Delivers 4.1% Weight Loss in Patients Switching From Injectables, Real-World OCTANE Data Show

In the OCTANE real-world analysis presented at EASD 2026, adults who switched from injectable semaglutide or tirzepatide to once-daily oral semaglutide lost an average of 4.1% of body weight after 3 months.

A disposable syringe is filled with a clear liquid and lies on a metal table. Disposable syringe with three glass vials of medicines. 3d render. | Image credit: © Alexandr - © Alexandr - stock.adobe.com

September 30th, 2026

Teva's Denosumab-Adet (Degevma) Approved as Xgeva Biosimilar

Denosumab-adet now covers all 3 Xgeva indications, widening lower-cost treatment access for cancer patients with bone complications.

Close up dermatitis on skin, ill allergic rash eczema skin of patient , atopic dermatitis symptom skin detail texture , Fungus of skin ,The concept dermatology, treatment fungal | Image credit: © InfiniteStudio - © InfiniteStudio - stock.adobe.com

September 30th, 2026

Lilly's Lebrikizumab Improves Hand-Foot Atopic Dermatitis

More than half of patients achieved clear or almost clear hands and feet with lebrikizumab by week 16, and 77% reported satisfaction with clearance.

Meeta Gulyani, SVP & GM of Bioprocessing and Head of Life Sciences Strategy at Ecolab Life Sciences, shares where biomanufacturing is headed next and why the relationship between drug developers and their suppliers is changing along with it.

SponsoredSeptember 30th, 2026

The Next Phase of Bioprocessing: Trends Redefining Manufacturing

Meeta Gulyani, Ecolab Life Sciences, shares where biomanufacturing is headed next and why the relationship between drug developers and their suppliers is changing along with it.

September 29th, 2026

The BioPharm Brief: Deals, Data, and a $2 Billion Bet

Novo Nordisk licenses a once-weekly oral GLP-1/GIP candidate, uniQure reports 48-month Huntington’s disease data, and AstraZeneca invests $2 billion in Summit Therapeutics.

Three injection pens labeled Wegovy, Ozempic, and Victoza crossed behind a bottle of Wegovy semaglutide 1.5 mg tablets on a white background. | Image Credit: © silukstockimages - stock.adobe.com

September 29th, 2026

Novo Nordisk Licenses Hengrui's Once-Weekly Oral GLP-1/GIP Dual Agonist HRS-1596 in Deal Worth Up to $2.6 Billion

Novo gains global rights, excluding Greater China, to HRS-1596, a phase 1-ready GLP-1/GIP dual receptor agonist that Hengrui says has potential for once-weekly oral dosing in obesity and type 2 diabetes.

Regenerative medicine and therapeutic stem cell therapy to regrow damaged cells as treatment for disease as multicellular organisms for cellular treatment of injury or arthritis illness due to aging | Image credit: © freshidea - © freshidea - stock.adobe.com

September 29th, 2026

iRegene's NouvSight001 Cleared for US and China RP Trials

NouvSight001 isn't limited to the RPE65-mutation subset current gene therapy treats, potentially reaching more of the 1.5 million with RP worldwide.